ArticleNature communications2023
CurveCurator: a recalibrated F-statistic to assess, classify, and explore significance of dose-response curves.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains.Molecular systems biology · 2026Article
- Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST.Nature communications · 2026Article
- Critical evaluation of drug response prediction models with DrEval.Nature communications · 2026Article
- Dose-Dependent Inhibition of Protein Glycosylation Reveals Crosstalk between Glycosylation and Phosphorylation in EGF Signaling Pathways.Analytical chemistry · 2026Article
- High-throughput chemical proteomics workflow for profiling protein citrullination dynamics.Nature communications · 2026Article
- Mapping drug mechanisms with ProteomicsDB: unified omics and cell sensitivity data at scale.Nucleic acids research · 2026Article
- Article
- From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons.International journal of molecular sciences · 2025Article
- BayesCurveFit: Enhancing Curve Fitting for Early-Stage Compound Screening Using Bayesian Inference.bioRxiv : the preprint server for biology · 2025Article
- High-Performance Proteomics Using Nano-, Capillary-, and Microflow Chromatographic Separations.Journal of proteome research · 2025Article
- ProSIMSIt: The Best of Both Worlds in Data-Driven Rescoring and Identification Transfer.Journal of proteome research · 2025Article
- PTMNavigator: interactive visualization of differentially regulated post-translational modifications in cellular signaling pathways.Nature communications · 2025Article
- Mendelian randomization analysis: exploring the causal relationship between menstrual cycle length and bone mineral density.Archives of medical science : AMS · 2025Article
- Characterizing protein-protein interactions with thermal proteome profiling.Current opinion in structural biology · 2024Review
- M2ara: unraveling metabolomic drug responses in whole-cell MALDI mass spectrometry bioassays.Bioinformatics (Oxford, England) · 2024Article
- Fudging the volcano-plot without dredging the data.Nature communications · 2024Article
- CurveCurator: a recalibrated F-statistic to assess, classify, and explore significance of dose-response curves.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dose-response curves are key metrics in pharmacology and biology to assess phenotypic or molecular actions of bioactive compounds in a quantitative fashion. Yet, it is often unclear whether or not a measured response significantly differs from a curve without regulation, particularly in high-throughput applications or unstable assays. Treating potency and effect size estimates from random and true curves with the same level of confidence can lead to incorrect hypotheses and issues in training machine learning models. Here, we present CurveCurator, an open-source software that provides reliable dose-response characteristics by computing p-values and false discovery rates based on a recalibrated F-statistic and a target-decoy procedure that considers dataset-specific effect size distributions. The application of CurveCurator to three large-scale datasets enables a systematic drug mode of action analysis and demonstrates its scalable utility across several application areas, facilitated by a performant, interactive dashboard for fast data exploration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.